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Confluence of Depression and Acute Psychological Stress Among
Patients With Stable Coronary Heart Disease: Effects on Myocardial
Perfusion
Matthew M. Burg, PhD; Judith Meadows, MD; Daichi Shimbo, MD; Karina W. Davidson, PhD; Joseph E. Schwartz, PhD; Robert Soufer, MD
Background-—Depression is prevalent in coronary heart disease (CHD) patients and increases risk for acute coronary syndrome
(ACS) recurrence and mortality despite optimal medical care. The pathways underlying this risk remain elusive. Psychological
stress (PS) can provoke impairment in myocardial perfusion and trigger ACS. A confluence of acute PS with depression might
reveal coronary vascular mechanisms of risk. We tested whether depression increased risk for impaired myocardial perfusion
during acute PS among patients with stable CHD.
Methods and Results-—Patients (N=146) completed the Beck Depression Inventory-I (BDI-I), a measure of depression linked to
recurrent ACS and post-ACS mortality, and underwent single-photon emission computed tomography myocardial perfusion imaging
at rest and during acute PS. The likelihood of new/worsening impairment in myocardial perfusion from baseline to PS as a function
of depression severity was tested. On the BDI-I, 41 patients scored in the normal range, 48 in the high normal range, and 57 in the
depressed range previously linked to CHD prognosis. A BDI-I score in the depressed range was associated with a significantly
greater likelihood of new/worsening impairment in myocardial perfusion from baseline to PS (odds ratio =2.89, 95% CI: 1.26 to
6.63, P=0.012). This remained significant in models controlling ACS recurrence/mortality risk factors and medications. There was
no effect for selective serotonin reuptake inhibitor medications.
Conclusions-—Depressed patients with CHD are particularly susceptible to impairment in myocardial perfusion during PS. The
confluence of PS with depression may contribute to a better understanding of the depression-associated risk for ACS recurrence
and mortality. ( J Am Heart Assoc. 2014;3:e000898 doi: 10.1161/JAHA.114.000898)
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P rospective observational studies show that amongpatients with CHD, elevated symptoms of depression
significantly increase the risk for recurrence of acute coronary
syndrome (ACS) events1 and early mortality,2 after adjustment
for CHD severity and medical comorbidities, and despite the
continued improvement in cardiologic care that has marked
the last 2 decades.2–7 Furthermore, post-ACS depression
clinical trials show no reduction in risk (cf. ref 8). Research on
the causal pathways or mechanisms through which depres-
sion confers risk has included autonomic dysregulation,
inflammation, platelet function, and behavioral mechanisms,
yet the findings of this research have been equivocal and thus
the key pathway or pathways remain elusive.9,10
In a recent review11 the multifactorial nature of ACS was
discussed, with the authors describing that ACS does not
result from a single factor, but rather from a confluence of
multiple factors that can give rise to coronary vascular
dysfunction, atherosclerotic plaque rupture, and thrombotic
cascade. Thus, investigation of only 1 variable in isolation,
such as depression, can provide merely an incomplete picture
that does not lead to a greater understanding of the
mechanistic underpinning between that variable and poor
prognosis in CHD patients. From this we proposed a model
informed by the confluence of depression with acute stress as
a triggering event that might better reveal key mechanisms of
risk linking depression to post-ACS outcomes.12
Research has shown that psychological stress can trigger
ACS and sudden cardiac death (cf. refs 13–16). The patho-
physiology of this stress-triggered ACS has been modeled
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under controlled laboratory conditions in studies that have
demonstrated coronary vascular dysfunction—impairment in
myocardial perfusion—provoked by acute psychological stress
(cf. refs 17–20). Of note, prior research has shown that among
patients with stable coronary disease, those with elevated
depression symptoms are more likely to evidence left ventric-
ular dysfunction during psychological stress administered
under controlled laboratory conditions.21,22 The purpose of
this study was to test whether depression increases the
likelihood of coronary vascular dysfunction—indexed by new
impairment in myocardial perfusion during acute psychological
stress—among patients with stable CHD.
Methods
Subjects
Patients with chronic stable CHD (n=146), documented by
history of ACS, surgical or percutaneous revascularization,
and/or a myocardial perfusion defect with exercise or
pharmacologic stress, were recruited from the cardiology
outpatient clinics at Yale University Medical Center and VA
Connecticut Healthcare System from January 2007 to Decem-
ber 2012. Patients with a diagnosis of ACS within 3 months of
the study, surgical or percutaneous revascularization within
6 months of the study, major cardiac arrhythmia or use of a
pacemaker or implantable cardioverter defibrillator, decom-
pensated heart failure, incapacitating or life-threatening illness,
major psychiatric disorder, cognitive impairment, pregnancy,
and/or inability to speak or read English were excluded. The
study complies with the Declaration of Helsinki, was approved
by the Institutional Review Board at both hospitals, and
informed consent was obtained from all patients.
Medical chart review and patient interview were used to
obtain demographic information and determine cardiovascular
risk profile, including history of ACS and/or revascularization.
Patients with a recent history of systolic blood pressure
>140 mm Hg, diastolic blood pressure >90 mm Hg, or
currently taking antihypertensive medication were classified
as having hypertension; those with total cholesterol of
>200 mg/dL, low-density lipoprotein of >130 mg/dL, or
taking cholesterol-lowering medications were classified as
having hypercholesterolemia. Use of b-blockers, aspirin,
statins, angiotensin-converting enzyme inhibitors, calcium-
channel blockers, and antidepressant medication was docu-
mented. Tobacco use was also determined. Patient charac-
teristics are described in Table 1.
Stress Procedure
As part of a larger investigation concerning the effects of
emotional stress on coronary vascular performance, patients
reported to the Yale University Cardiovascular Behavioral
Medicine Research Laboratory at 9 AM on the day of study.
Patients were asked to eat a light breakfast and take their
normal medications, and adherence to this was confirmed on
their arrival. Patients completed a questionnaire battery that
included the Beck Depression Inventory-I (BDI-I), a 21-item self-
report questionnaire designed to assess depression symptom
severity.23 Each of the items in this questionnaire describes a
symptom or characteristic of the depression constellation, and
respondents indicate on a 0 to 3 scale the intensity with which
they have experienced the symptom in the past 2 weeks. This
questionnaire has been used in studies of patients with stable
CHD and after ACS, and in particular, scores of ≥10 have been
linked to increased risk for major adverse cardiac events and
mortality in these populations.24 The Cronbach’s a for total
BDI-I scale for the current sample was 0.92.
After completing the questionnaire, an indwelling intrave-
nous catheter was inserted in the patient’s nondominant arm.
Both resting and psychological stress single-photon emission
computed tomography (SPECT) myocardial perfusion imaging
scans were performed on the same day. Under resting
conditions, the patient received intravenous injection of 10 to
12 mCi 99mTc tetrofosmin (Myoview, GE Healthcare, Bucking-
hamshire, England). Resting SPECT imaging was acquired 30 to
45 minutes after injection. On completion of rest imaging, the
patient was removed from the camera and escorted to the
laboratory room, where the psychological stress testing was
performed. A 30-minute rest period was initiated, followed by a
standard psychological stress protocol (cf. refs 17, 25) that
included a formal 10-minute resting baseline condition. For the
baseline condition, patients were instructed to close their eyes
and imagine being in a restful setting.
After completion of baseline, the 6-minute acute psycho-
logical stress condition (PS) was initiated. For this condition,
mental arithmetic—serial subtraction—was used, as it is a
particularly potent stress task for both male and female
patients of diverse backgrounds.17,25 Starting with a 4-digit
number, patients were instructed to subtract a specified
number (eg, “7”) serially. Following a standard protocol, the
patient was instructed to work as quickly and accurately as
they could, and they were both frequently prompted to work
faster, and firmly corrected when they made errors. The
frequency of prompts was titrated to incur an error rate of 1
per 10 calculations, as we have described previously (cf. refs
17, 25), and this was achieved with all patients. Approxi-
mately 1 minute into the PS condition, 30 to 32 mCi 99mTc
tetrofosmin was injected, with acquisition of SPECT imaging
approximately 45 to 60 minutes later.
Monitoring during the laboratory protocol was identical to
that done for clinical stress testing. In brief, HR, systolic/
diastolic blood pressure, and 12-lead ECG were obtained at
5-minute intervals during baseline and at 1-minute intervals
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during PS. Indication for early termination of PS likewise was
identical to clinical stress testing: angina or symptom
equivalent, ST-segment depression of >3 mm, drop in systolic
blood pressure, or any arrhythmia, though none of these
indications occurred during the protocol.
SPECT Myocardial Perfusion Imaging
Radiotracer dosing, image acquisition, and image processing
were performed according to guidelines of the American
Society of Nuclear Cardiology26 and followed a protocol
identical to that used clinically in the low dose/high dose
single-day protocol with rest imaging performed prior to
stress imaging. Gated SPECT was performed with use of a
step-and-shoot acquisition on a Philips Forte gamma camera
system with Gd-153 line source attenuation correction or on a
GE Discovery SPECT/CT system with CT-based attenuation
correction. Data were acquired over 180 degrees, with 64
frames with a 64964 matrix, 8 frame gating, and 20% window
centered on 140 keV photo peak of 99mTc.
Tomographic images were reconstructed using standard
filtered backprojection and Butterworth low-pass filtering,
using JET Stream platform (Philips Medical Systems, Milpitas,
CA). Short- and long-axis SPECT slices were generated, along
with multilevel gated cines. Reconstructed images were
interpreted using AUTOQUANT (Cedars-Sinai, Los Angeles,




Perfusion Defect During PS BDI Score
No (N=67) Yes (N=79)
Normal Score 0 to 4
(N=41)




Age (SD) 66 (9) 66 (10) 67 (9) 65 (8) 68 (10) 66 (9)
Sex (% male) 76 77 75 77 77 74
LVEF % (SD)* 56 (11) 56 (13) 55 (10) 55 (11) 56 (10) 56 (13)
Hyperlipidemia (%) 91 91 92 95 88 93
Diabetes (%) 33 30 36 24 44 30
Hypertension (%) 83 85 81 80 83 84
Tobacco use (%) 34 39 31 39 27 38
Mean BDI score (SD) 10.5 (9.2) 8.6 (7.9) 12.0 (9.9) 2.0 (1.3) 7.0 (1.4) 19.4 (8.3)
Medications
Aspirin (%) 78 76 79 76 85 73
Statin (%) 92 91 94 88 90 98
b-Blocker (%) 81 79 83 80 83 80
Plavix (%) 21 26 17 32 21 13
Ca-channel blocker (%) 34 31 37 37 35 32
ACE inhibitor (%) 43 42 43 41 40 46
SSRI (%) 21 16 25 0 25 33
Severity of coronary disease
MPI defect on exercise/
Pharmacologic stress (%)
54 55 54 49 54 59
Prior ACS (%) 52 48 55 50 52 53
Prior PCI (%) 51 54 48 53 46 49
Number vessels (SD) 1.60 (0.96) 1.72 (0.89) 1.50 (1.03) 1.63 (0.97) 1.65 (0.99) 1.58 (1.01)
Prior CABG (%) 44 40 47 42 44 46
Number vessels (SD) 3.17 (1.00) 3.07 (0.99) 3.26 (1.01) 3.17 (0.98) 3.17 (0.99) 3.19 (1.02)
Months since revascularization
(SD)
78 (72) 74 (73) 81 (71) 78 (72) 76 (71) 79 (82)
ACE indicates angiotensin converting enzyme; ACS, acute coronary syndrome; BDI, Beck Depression Inventory; Ca, calcium; CABG, coronary artery bypass graft surgery; LVEF, left
ventricular ejection fraction; MPI, myocardial perfusion imaging; PCI, percutaneous coronary intervention; PS, psychological stress; SSRI, selective serotonin reuptake inhibitor.
*LVEF value taken from the most recent diagnostic test in the medical record (eg, resting cardiac echocardiogram/single-photon emission computed tomography MPI, cardiac
catheterization).
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CA). Myocardial perfusion images were independently ana-
lyzed and interpreted by 2 experienced nuclear cardiologists
(R.S., J.M.) blinded to the name and risk profile of the patients,
and all other medical data, including depression status. The
concordance rate was 95%, with discordant studies addressed
by another joint review where consensus was reached.
Perfusion, wall motion, and wall thickening were assessed
in a qualitative and a semiquantitative manner. Perfusion
images were analyzed in both a gray-scale and color display.
Rest and stress images were visually compared for number
and severity of perfusion defects using a 17-segment model.
Each segment was scored from 0 to 4, with 0 being “normal
uptake” and 4 being “no uptake,” yielding a total score. A
reversible defect score (summed difference score) was
calculated as the difference between summed PS and
summed rest scores. Following published guidelines,26 a
new impairment in myocardial perfusion during PS compared
with the resting baseline images in a segment was defined as
a score ≥2 (definitely abnormal); a worsening impairment was
defined as an increase in score ≥1 above a score of 2 or
greater. If any of the 17 segments evidenced these scores,
the patient was categorized as having new/worsening
impairment in myocardial perfusion during PS.
Data Analysis
From the overall sample, 3 groups of patients were created
based on BDI-I scores, using an approach previously reported
in the literature6,27: those with a score <5 (not depressed),
those with a score of 5 to 9 (high normal), and those with a
score ≥10 (depressed), the latter range having been linked in
multiple studies to risk for recurrent ACS/mortality (cf. refs 1,
2, 24). We report descriptive statistics for the total sample,
and separately by depression group and for myocardial
perfusion response to PS. Group differences in percentages
were tested using the v2 test of independence; t tests, and 1-
way ANOVA were used to test for differences in means
between groups with and without new/worsening myocardial
perfusion from baseline to PS, and among depression groups,
respectively. Using logistic regression, we estimated and
tested the unadjusted odds ratios for new/worsening impair-
ment in myocardial perfusion from baseline to PS for those in
the depressed group and the high normal group, relative to
the not-depressed group. Three multiple logistic regression
models were then estimated with the inclusion of the
following covariates:
Model 1: ACS recurrence/mortality risk factors—age, left
ventricular ejection fraction (LVEF), hypertension, hypercho-
lesterolemia, diabetes, and tobacco use;
Model 2: medications—aspirin, statin, b-blocker, and Plavix;
Model 3: ACS recurrence/mortality risk factors and medica-
tions.
Depression status based on BDI-I score and use of an SSRI
were inherently correlated (P<0.001), and thus we did not
want to treat SSRI medication use as a potential confounder
unless it was also correlated with the likelihood of a new/
worsening impairment in myocardial perfusion from baseline
to PS; 51.3% of the 115 participants not taking a selective
serotonin reuptake inhibitor (SSRI) and 64.5% of the 31 taking
an SSRI had this new/worsening impairment (P=0.23 by
Fisher’s exact test). Based on this result, SSRI use was not
included in the multivariable analyses. Given the relatively
small sample size, effect modification was not examined.
Finally, we performed a sensitivity analysis in which all
models were re-estimated, treating depression symptoms as a
continuous predictor (square-root transformed to reduce the
positive skewness of the distribution).
Results
Demographics
Of the overall N=146 sample, 41 (28%) patients scored in the
not-depressed range on the BDI-I, 48 scored in the high
normal range (33%), and 57 (39%) in the depressed range.
Figure 1 contains a histogram portraying the distribution of
BDI-I scores. The average age was 66 (9) years. Approxi-
mately 76% were male, 92% were classified as hyperlipidemic,
83% as hypertensive, 33% as diabetic, and 34% as tobacco
user; 78% were taking aspirin, 92% a statin, 81% a b-blocker,
21% Plavix, 43% an angiotensin converting enzyme inhibitor,
34% a calcium channel blocker, and 21% an SSRI antidepres-
sant. In addition, the average LVEF extracted from the medical
record was 55.8%, while 52% had a previous ACS, and 51%
had previous percutaneous and 44% surgical revasculariza-
tion, with an average 78 months since revascularization
Figure 1. Distribution of Beck Depression Inventory-I (BDI-I)
scores.
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(Table 1). There were no statistically significant differences in
these variables between those with versus without new/
worsening impairment in myocardial perfusion from baseline
to PS, or with the exception of SSRI, between the 3
depression groups.
Hemodynamics and SPECT-Derived LVEF
At resting baseline, the average systolic blood pressure was
133 (20) mm Hg, average diastolic blood pressure was 73
(12) mm Hg, and average heart rate was 59 (12), while the
average LVEF derived from SPECT myocardial perfusion
imaging was 56.0 (10.8). With PS this increased to a
systolic/diastolic blood pressure of 151 (19)/82 (9) mm
Hg, and heart rate of 67 (11), while the SPECT myocardial
perfusion imaging–derived LVEF was 56.9 (11.6). There
were no statistically significant differences in these variables
between those with versus without new/worsening impair-
ment in myocardial perfusion during PS, or between the 3
depression groups. The apparent lack of change in LVEF from
baseline to PS is not surprising since the PS SPECT images
were acquired 45 to 60 minutes after the stress. While the
perfusion images acquired at that time reflect perfusion at the
time of injection (eg, at the time of the stress) the gated wall
motion images on which LVEF is derived reflect wall motion at
the time of acquisition (eg, 45 to 60 minutes after injection), a
time when any deficits in LVEF provoked by psychological
stress would be expected to have normalized (Table 2).
Depression and New/Worsening Impairment in
Myocardial Perfusion During PS
Overall, 79 (54%) patients demonstrated a new/worsening
impairment in myocardial perfusion from baseline to PS
(Table 3). This included 16 (39%) of those with BDI-I score
from 0 to 4 (no depression), 26 (54%) with BDI-I score of 5 to 9
(high normal), and 37 (65%) with BDI-I score of ≥10
(depressed). The unadjusted logistic regression analysis
revealed a statistically significant greater likelihood of this
new/worsening impairment for those having a BDI-I score in
the depressed range, compared to those with no depression
(odds ratio=2.89, 95% CI: 1.26 to 6.63, P=0.012); the greater
likelihood for those having a BDI-I score in the high normal
range was consistent with a dose–response relationship, but
not statistically significant (odds ratio=1.85, 95% CI: 0.79 to
4.30, ns). Having a BDI-I score in the depressed range
remained a significant predictor of a new or worsening
impairment in myocardial perfusion during PS in separate
subsequent models controlling for (a) age, LVEF, hypertension,
hypercholesterolemia, diabetes, and tobacco use (odds
ratio=3.43, 95% CI: 1.43 to 8.25, P=0.006); (b) aspirin, statin,
b-blocker, and Plavix medications (odds ratio=2.63, 95% CI:
1.11 to 6.23, P=0.028); and (c) with both sets of covariates in a
single model (odds ratio=3.38, 95% CI: 1.35 to 8.49, P=0.01)
(Table 4). While in each case a BDI-I score in the high normal
range was not a significant predictor of impaired myocardial
perfusion during PS, the increase in likelihood was approxi-
mately 50% of that for those with a BDI-I score in the depressed
range. These analyses were also repeated using BDI-I score as
a continuous variable, with comparable results (Table 5).
In the sensitivity analyses in which depression group was
replaced by the continuous BDI-I score (square-root trans-
formed), the association between depressive symptoms and
the likelihood of a new/worsening impairment in myocardial
perfusion from baseline to PS remained statistically significant
(Table 5).
A locally weighted scatterplot smoothing (LOESS) curve of
the bivariate relationship between BDI-I score and the
Table 2. Heart Rate, Blood Pressure, and Ejection Fraction at Resting Baseline and Acute Psychological Stress
Heart Rate and Blood Pressure
MPI Ejection Fraction*Baseline Change With PS
SBP (mm Hg) DBP (mm Hg) HR (bpm) SBP (mm Hg) DBP (mm Hg) HR (bpm) Rest PS
BDI score
Normal score 0 to 4 (N=41) 13620 748 5911 1614 96 86 55.810.8 57.311.6
Hi-Normal score 5 to 9 (N=48) 12817 707 6410 1711 96 76 56.010.7 56.711.4
Depressed score ≥10 (N=57) 13120 7215 5812 1513 79 77 56.410.9 56.911.7
New/Worse impairment in myocardial perfusion during PS
No (N=67) 13421 7310 6011 1312 86 66 55.8010.19 55.4411.06
Yes (N=79) 12924 7113 6012 1813 98 87 56.2211.18 58.3011.67
BDI indicates Beck Depression Inventory; bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; mm Hg, millimeters of mercury; MPI, myocardial perfusion imaging; PS,
psychological stress; SBP, systolic blood pressure.
*Ejection fraction associated with PS was obtained from gated images 45 to 60 minutes post stress; thus, any effect of stress on ejection fraction would be expected to no longer be
present, and this is what was found.
DOI: 10.1161/JAHA.114.000898 Journal of the American Heart Association 5















probability of new/worsening myocardial perfusion defect
from baseline to PS was generated (Figure 2). In this relatively
small sample, the LOESS curve does not fit the data
significantly better than a straight line (P=0.22).
Discussion
In what we believe to be the first reported test of whether the
confluence of depression and acute psychological stress
affects coronary vascular function, we found that a score on
the BDI-I indicative of depression and previously linked to ACS
recurrence and mortality risk was associated with a substan-
tially greater likelihood (odds ratio of 2.6 to 3.4) of a new or
worsening impairment in myocardial perfusion during such
stress, independent of ACS recurrence risk factors and
medications. We furthermore found that an intermediate
score of high normal on the BDI-I increased this likelihood in a
dose–response manner (odds ratio of 1.7 to 1.9), though this
was not statistically significant; the study was underpowered
to detect associations of this magnitude. Thus, the cur-
Table 3. Myocardial Perfusion at Rest and During Psychological Stress
Total
BDI Score
Normal Score 0 to 4 Hi-Normal Score 5 to 9 Depressed Score ≥10
New 66 9 22 35
Worse 53 7 20 26
Patients with new/worse MPI defect (N=79) (N=16) (N=26) (N=37)
SRS 3.59 (3.30) 4.25 (3.63) 2.10 (2.47) 4.20 (3.74)
SSS 9.41 (4.24) 8.38 (4.67) 9.10 (3.84) 9.00 (4.34)
SDS 5.82 (2.24) 4.13 (2.29) 7.00 (3.25) 4.80 (1.51)
Patients without new/worse MPI defect (N=67) (N=25) (N=22) (N=20)
SRS 2.66 (2.48) 2.79 (2.16) 2.90 (2.73) 2.23 (2.20)
SSS 4.13 (3.02) 3.68 (1.89) 4.55 (3.45) 4.23 (3.96)
SDS 1.47 (1.41) 0.89 (0.50) 1.65 (1.38) 2.00 (2.58)
Values for SRS, SSS, and SDS are mean (SD). BDI indicates Beck Depression Inventory-I; MPI, myocardial perfusion imaging; SDS, sum defect score; SRS, sum rest score; SSS, sum stress
score.
Table 4. Logistic Regression Models Predicting New/Worsening Impairment in Myocardial Perfusion From Baseline to PS From











High normal vs Normal 1.85 (0.79 to 4.30) 1.80 (0.74 to 4.38) 1.82 (0.77 to 4.30) 1.73 (0.70 to 4.33)
Depressed vs Normal 2.89* (1.26 to 6.63) 3.43** (1.43 to 8.25) 2.63* (1.11 to 6.23) 3.38** (1.35 to 8.49)
Age (per 10-year increase) 1.00 (0.67 to 1.47) 0.99 (0.66 to 1.50)
LVEF (per 10% increase) 0.86 (0.63 to 1.18) 0.85 (0.61 to 1.18)
Hypertension 0.70 (0.26 to 1.73) 0.62 (0.23 to 1.64)
Hypercholesterolemia 1.32 (0.37 to 4.64) 1.29 (0.36 to 4.68)
Diabetes 1.23 (0.57 to 2.65) 1.18 (0.54 to 2.60)
Tobacco use 0.74 (0.35 to 1.59) 0.73 (0.33 to 1.58)
Aspirin 1.22 (0.52 to 2.82) 1.63 (0.67 to 3.94)
Statin 1.07 (0.32 to 3.56) 0.76 (0.20 to 2.84)
b-Blocker 1.43 (0.60 to 3.40) 1.47 (0.56 to 3.84)
Plavix 0.67 (0.28 to 1.56) 0.60 (0.25 to 1.47)
ACS indicates acute coronary syndrome; LVEF, left ventricular ejection fraction; OR, odds ratio; PS, psychological stress.
*P≤0.05, **P≤0.01.
DOI: 10.1161/JAHA.114.000898 Journal of the American Heart Association 6















rent findings reveal one potential and previously untested
pathway—vulnerability in the coronary vasculature—that may
underlie the ACS recurrence and mortality risk associated
with depression.
Although depression is prevalent and marks ACS recurrence
and mortality risk among patients with CHD,1–7 an understand-
ing of the causal pathways or mechanisms through which this
risk is conferred remains elusive.9,10 The multifactorial nature
of ACS is increasingly recognized.11 This led us to recently
propose 12 that the equivocal findings in the literature regarding
such factors as inflammation, platelet function, autonomic
dysregulation, and medication adherence as underlying the
relationship of depression to ACS recurrence and mortality risk
may in part reflect a failure to consider additional, activating
factors. We therefore offered a new model defined by the
confluence of depression with acute psychological stress as a
possible activating factor for elucidating critical pathways, and
thus contributing to a more precise understanding of depres-
sion-associated risk.12 In the current study we tested this
model, specifically with regard to dynamic coronary perfusion
and thus, coronary vascular processes, and the findings provide
credence to the proposed paradigm and support its use in
future larger studies aimed at understanding the depression-
associated risk for ACS recurrence and mortality.
Depression and Vascular Function
To understand the pathophysiological processes by which
depression influences coronary vascular performance during
acute psychological stress, it is essential to recognize the
dynamic nature of the observed impairment in myocardial
perfusion. Specifically in the current study, there were no
depression-related differences—or differences between those
with and without impairment in myocardial perfusion during
acute psychological stress—in the prior occurrence of ACS, in
prior revascularization, or in the severity of myocardial
perfusion impairment with exercise or pharmacologic stress.
Thus, differences in coronary anatomy are not likely to account
Table 5. Logistic Regression Models Predicting New/Worsening Impairment in Myocardial Perfusion From Baseline to PS From












1.37* (1.07 to 1.76) 1.42** (1.09 to 1.84) 1.33* (1.03 to 1.72) 1.40* (1.07 to 1.84)
Age (per 10-year increase) 0.96 (0.65 to 1.42) 0.95 (0.63 to 1.43)
LVEF (per 10% increase) 0.85 (0.62 to 1.17) 0.84 (0.60 to 1.17)
Hypertension 0.67 (0.26 to 1.73) 0.62 (0.24 to 1.64)
Hypercholesterolemia 1.26 (0.37 to 4.35) 1.25 (0.35 to 4.43)
Diabetes 1.18 (0.56 to 2.52) 1.14 (0.52 to 2.48)
Tobacco use 0.74 (0.35 to 1.58) 0.74 (0.34 to 1.59)
Aspirin 1.24 (0.54 to 2.85) 1.58 (0.66 to 3.76)
Statin 1.04 (0.32 to 3.46) 0.83 (0.22 to 3.06)
b-Blocker 1.42 (0.60 to 3.36) 1.44 (0.56 to 3.75)
Plavix 0.66 (0.28 to 1.54) 0.58 (0.24 to 1.40)
ACS indicates acute coronary syndrome; BDI, Beck Depression Inventory-I; LVEF, left ventricular ejection fraction; OR, odds ratio; PS, psychological stress.
*P≤0.05, **P≤0.01.
Figure 2. LOESS curve of the bivariate relationship between Beck
Depression Inventory (BDI) score and the probability of new/
worsening myocardial perfusion defect from baseline to psycho-
logical stress (PS). Dark black line shows the relationship between
BDI score and the predicted probability of new/worsening impair-
ment in myocardial perfusion from baseline to PS. The blue bands
around this line outline the 95% CI. In this relatively small sample,
the LOESS curve does not fit the data significantly better than a
straight line (P=0.22). MPI indicates myocardial perfusion imaging.
LOESS indicates locally weighted scatterplot smoothing curve.
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for the main finding. Furthermore, the increase in myocardial
oxygen demand during the acute psychological stress, as
reflected by increases in heart rate and blood pressure,
similarly showed no difference, and indeed, was lower than the
increase in demand that typically occurs during exercise-
provoked impairment in perfusion. Rather, these data point to a
likely dynamic coronary obstruction17,28,29 whereby some
aspect of underlying vulnerability in the coronary vasomotor
response to psychological stress is specifically revealed among
CHD patients as a function of depression.
Prior research has shown that depression is associated with
disruption in vascular processes (ie, endothelial dysfunction30
and impairment in coronary flow reserve31) that could account
in part for the current findings and for increased ACS/mortality
risk. We have shown in 1 small study of stable CHD patients
that psychological versus pharmacologic stress is predomi-
nately associated with impaired coronary vascular function in
coronary distributions without obstructive atherosclerotic
plaques,28 a finding that must be confirmed in larger studies.
Others have demonstrated epicardial vasoconstriction during
acute psychological stress at the site of epicardial coronary
segments with minimal atherosclerosis.29 Thus, impairment
may be more broadly evident throughout the coronary vascu-
lature. Furthermore, we have observed a level of endogenous
endothelin-1 (ET-1) among depressed CHD patients that has
previously been linked to myocardial infarction recurrence.32
We have also observed that circulating ET-1 increases during
acute psychological stress.32–34 ET-1, the most potent endog-
enous vasoconstricting agent, is secreted by endothelial cells
and macrophages, and in the setting of coronary atheroscle-
rosis is responsible to the greatest extent for coronary
vasoconstriction.35 ET-1 also acts synergistically with norepi-
nephrine,36 to accentuate dynamic vasoconstriction, and we
have previously observed that acute psychological stress
provokes an increase in circulating norepinephrine among CHD
patients.17,33,34 Of note, depression is associated with auto-
nomic dysregulation, defined in part by an increase in
sympathetic activity.37 While serological data on norepineph-
rine and ET-1 were not available for the current analyses, the
data are nonetheless intriguing, and highlight that a consider-
ation of stress as an “activating” process may lead to a better
understanding of the link between depression and recurrent
ACS/mortality, rather than the inconsistent puzzle that is
defined by the literature.12 It may be that the identification of
mechanisms—and thus potential treatment targets—of
depression-related ACS recurrence/mortality risk requires
that we psychologically “stress” the depressed CHD patient.
Strengths
To the best of our knowledge, this is the first study to
specifically examine the confluence of depression and acute
psychological stress as they relate to dynamic impairment in
coronary vascular function, a process that can serve to initiate
an ACS event.11 It is important to note that 2 earlier studies
demonstrated impairment in ventricular function during psy-
chological stress in relation to depression; 1 study used
radionuclide ventriculography21 and 1 used cardiac ultra-
sound.22 Furthermore, a recent clinical trial of the SSRI
antidepressant medication escitalopram demonstrated a
benefit for this medication on mental stress–provoked
impairment in ultrasound-assessed ventricular function
regardless of depression status,38 though in the current
study we found no such effect for this class of medications on
the likelihood of a new or worsening myocardial perfusion
defect provoked by psychological stress. When viewed in the
context of the current findings and prior research on the
pathways responsible for “mental stress–provoked myocardial
ischemia,” these prior studies raise important questions.
The issue of myocardial perfusion versus ventricular
function—“flow versus function”—in research concerning
the effects of psychological stress on the heart has been the
focus of recent editorials39,40 and of research for approx-
imately 30 years, since the publication by Deanfield et al20 in
which it was reported that, using positron emission tomog-
raphy rubidium, psychological stress provoked a myocardial
perfusion defect. Later studies by Arrighi et al using positron
emission tomography,28 and both Yeung et al29 and Boltwood
et al41 in the cath lab, demonstrated that the static flow-
limiting plaque model was at best inaccurate when applied to
the effects of psychological stress, in that this form of stress
caused coronary vasoconstriction. These data also helped
solve the riddle of why “ischemia” during mental stress was
observed in the context of a lower myocardial oxygen
demand, when compared with “ischemia” during exercise/
pharmacologic stress.17,25 These data also served to highlight
a pathway by which psychological stress could lead to plaque
rupture (eg, through coronary vasomotion at the site of a
vulnerable plaque).11
The issue of sensitivity/specificity as concerns “flow
versus function” was further highlighted by the Psychophys-
iological Investigations of Myocardial Ischemia study investi-
gators, who reported both a decrement in function during
psychological stress among healthy individuals, and further-
more, an increase in peripheral resistance and thus afterload,
during psychological stress; this increase in afterload is also
likely to affect ventricular function, particularly among the
patient population typically studied (those with already
impaired ventricular function secondary to previous
infarct).42,43 We have also previously shown substantial
discordance between wall motion abnormality/left ventricular
dysfunction and new/worsening myocardial perfusion defect
during psychological stress.44 This discordance is not surpris-
ing, since along the ischemic cascade, an acute impairment in
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myocardial blood flow is more proximal than a decrement in
ventricular performance.45 It may be that because psycho-
logical stress appears to uniquely affect dynamic coronary
vasomotion versus physical or pharmacologic stress, the
phenomena being indexed by myocardial perfusion versus
ventricular function are somewhat distinct. This has led us to
conclude that SPECT myocardial perfusion imaging may be
the better choice in studies concerning the effects of
psychological stress on the heart.40
Limitations
While the current findings lend support to the utility of a
depression–acute psychological stress confluence in the
effort to understand the ACS recurrence/mortality risk
associated with depression, the study is not without limita-
tions. The sample was heterogeneous, comprised stable
patients who were far removed from their most recent ACS
event or revascularization, and the coronary anatomy at the
time of the study was not known. Thus, these findings may
not be applicable to an understanding of depression-associ-
ated prognosis soon after ACS. In addition, while hemody-
namic indices and detailed information regarding underlying
coronary disease were available for analysis, serum markers—
including of ET-1 and indices of inflammation—and other
related measures of autonomic and endothelial function were
not. The sample size was also relatively small, and many of the
statistical tests failed to reach significance. This may have
included the absence of an effect for SSRI medications on the
likelihood of a psychological stress–provoked myocardial
perfusion defect, and indeed, this class of medications may
still be useful for cardiac patients with comorbid depression.
Replication with a larger sample that ismore proximal to an ACS
event and that includes these measures should provide a more
complete test of the stress–depression paradigm and an
understanding of the depression-associated risk for poor
prognosis after ACS.
An additional issue concerns whether the impairment in
myocardial perfusion observed as a function of depression
was because depressed patients have a lower ischemic
threshold in general (eg, due to a greater vascular vulnera-
bility). It is also possible that depressed patients are more
susceptible to psychological stress (eg, that the serial
subtraction task was more stressful for them). Future studies
should include an exercise or pharmacologic stress condition,
and should include a self-report measure of task stressfulness
to address these issues.
In summary, we found that stable CHD patients with
depression were more likely to demonstrate a new or
worsening impairment in myocardial perfusion during acute
psychological stress, with evidence of a dose–response
relationship. This could not be accounted for by markers of
the underlying extent of coronary atherosclerosis, medical
comorbidity and traditional risk factors, or medications. These
preliminary findings lend credence to a confluence of
depression with acute psychological stress for understanding
the contribution of depression to ACS recurrence and
mortality. Future studies with larger cohorts will be able to
address the question of whether this effect of acute
psychological stress on myocardial perfusion accounts for
the greater risk of recurrent ACS/mortality associated with
depression.
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